Claims for Patent: 6,287,806

Summary for Patent: 6,287,806

Title:	Method for producing a biologically active recombinant cysteine-free peptide
Abstract:	A cysteine-free peptide is produced by producing a fused protein comprising a protein having cysteine at its N-terminal and a cysteine-free peptide ligated to the N-terminal and subsequently subjecting the fused protein to a reaction for cleaving the peptide linkage.
Inventor(s):	Nishimura; Osamu (Kawanishi, JP), Kuriyama; Masato (Osaka, JP), Koyama; Nobuyuki (Osaka, JP), Fukuda; Tsunehiko (Kyoto, JP)
Assignee:	Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:	09/108,661
Patent Claims:	1. A method for producing a cysteine-free peptide for pharmaceutical use, which comprises cultivating a transformant having a vector carrying a gene coding for a fused protein comprising a protein having cysteine at its N-terminal and a cysteine-free peptide ligated to the N-terminal to express said fused protein, and subjecting the expressed fused protein to reaction for cleaving the peptide linkage on the amino group side of the cysteine residue, wherein the reaction for cleaving the peptide linkage is conducted by a cyanylation reaction by using a S-cyanylation reagent followed by (i) hydrolysis to produce a carboxy peptide at the C-terminal end of the cysteine-free polypeptide, or (ii) aminolysis to produce an amide or substituted amide derivative at the C-terminal end of the cysteine-free polypeptide, and isolating the cysteine-free polypeptide. 2. The method of claim 1, wherein an amino compound or a substituted amino compound is used for cleaving the peptide linkage to produce an amide or substituted amide derivative of the cysteine-free peptide. 3. The method of claim 1, wherein the fused protein comprises (1) a protein having cysteine at its N-terminal with molecular weight of 300 to 50,000 and (2) a cysteine-free polypeptide having molecular weight of 200 to 7000 ligated to the N-terminal of said protein (1). 4. The method of claim 1, wherein the cysteine-free peptide is glucose-dependent insulinotropic polypeptide (GIP). 5. The method of claim 1, wherein the cysteine-free peptide is glucagon-like peptide I (GLPI). 6. The method of claim 1, wherein the cysteine-free polypeptide is selected from the group consisting of adrenocorticotropic hormone (ACTH), parathyroid hormone (PTH), enkephalins, endorphins, opioid peptides, .beta.-melanocyte stimulating hormone, glucose-dependent insulinotropic polypeptide (GIP), glucagon, glucagon-like peptides (GLP-I and II), motilin, thymopoietins, thyosins, ubiquitine, serum thymic factor, thymic humoral factor, quininese, neurotensin, tuftsin and fragments of these peptides. 7. The method of claim 1, wherein the cysteine-free polypeptide is selected from the group consisting of gastrin, calcitonin, calcitonin gene associated peptide, cholecystokinin-pancreozymin (CCK-PZ), eledoisin, epithelial growth factor (EGF), tumor growth factor (TGF-.alpha.), pancreastatin, insulin, insulin-like growth factor, luteinizing hormone-releasing hormone (LH-RH), mellitin, oxytocin, vasopressins, pancreatic polypeptide, trysin inhibitor, relaxin, secretin, somatostatins, somatomedins, substance P, neurotensin, caerulein, thyrotropin-releasing hormone (TRH), vasoactive intestinal polypeptide (VIP), pituitary adenyl cyclase-activating polypeptides (PACAPs), gastnin-releasing peptide (GRP), endothelins, corticotropin-releasing factor (CFR), growth hormone-releasing factor (GRF), PTH-related protein, gallanin, peptide YY, neuropeptide Y pancreastatin, atrial natriuretic peptides, and fragments of these peptides. 8. The method of claim 1, wherein the protein having cysteine at its N-terminal is selected from the group consisting of growth factors, enzyme proteins, storage proteins, streptoavidin, protein A, protein G and tissue plasminogen activator (TPA). 9. The method of claim 8, wherein the growth factor is selected from the group consisting of interferons, interleukins and fibroblast growth factor (FGF). 10. The method of claim 8, wherein the enzyme protein is selected from the group consisting of urokinase, prourokinase, lymphotoxin, tumor necrosis factor (TNF) and .beta.-galactosidase. 11. A method for producing a cysteine-free peptide for pharmaceutical use, which comprises constructing a gene which codes for a protein having a structure in which a cysteine-free peptide is ligated to the N-terminal of a peptide having cysteine at its N-terminal, cultivating a transformant harboring a vector carrying said gene to express the protein, and subjecting the expressed fused protein to reaction for cleaving the peptide linkage on the amino group side of the cysteine residue, wherein the reaction for cleaving the peptide linkage is conducted by a cyanylation reaction by using a S-cyanylation reagent followed by (i) hydrolysis to produce a carboxy peptide at the C-terminal end of the cysteine-free polypeptide, or ii) aminolysis to produce an amide or substituted amide derivative at the C-terminal end of the cysteine-free polypeptide, and isolating the cysteine-free polypeptide. 12. The method of claim 11, wherein an amino compound or a substituted amino compound is used for cleaving the peptide linkage to produce an amide or substituted amide derivative of the cysteine-free peptide. 13. The method of claim 11, wherein the fused protein comprises (1) a protein having cysteine at its N-terminal with molecular weight of 300 to 50,000 and (2) a cysteine-free polypeptide having molecular weight of 200 to 7000 ligated to the N-terminal of said protein (1). 14. A method for producing a cysteine-free polypeptide which comprises cultivating a transformant having a vector carrying a gene coding a polypeptide wherein an amino acid of said polypeptide has been replaced with cysteine, expressing said polypeptide, subjecting the expressed polypeptide to a reaction for cleaving the peptide linkage on the amino group side of cysteine residue, wherein the reaction for cleaving the peptide linkage is conducted by a cyanylation reaction by using S-cyanylation reagent followed by hydrolysis to produce a carboxy peptide and isolating said cysteine-free polypeptide.

Details for Patent 6,287,806

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2011-02-19
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2011-02-19